期刊
PROTEOMICS CLINICAL APPLICATIONS
卷 10, 期 1, 页码 58-74出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.201500020
关键词
Chronic kidney disease; Polycystic kidney disease; Targeted proteomics; Urine
资金
- NIH [UL1 RR024139, S10RR026707, P30 DK079310, P30 DK090744, K24DK090203]
PurposeSince human urine is the most readily available biofluid whose proteome changes in response to disease, it is a logical sample for identifying protein biomarkers for kidney diseases. Experimental designPotential biomarkers were identified by using a multiproteomics workflow to compare urine proteomes of kidney transplant patients with immediate and delayed graft function. Differentially expressed proteins were identified, and corresponding stable isotope labeled internal peptide standards were synthesized for scheduled MRM. ResultsThe Targeted Urine Proteome Assay (TUPA) was then developed by identifying those peptides for which there were at least two transitions for which interference in a urine matrix across 156 MRM runs was <30%. This resulted in an assay that monitors 224 peptides from 167 quantifiable proteins. Conclusions and clinical relevanceTUPA opens the way for using a robust mass spectrometric technology, MRM, for quantifying and validating biomarkers from among 167 urinary proteins. This approach, while developed using differentially expressed urinary proteins from patients with delayed versus immediate graft function after kidney transplant, can be expanded to include differentially expressed urinary proteins in multiple kidney diseases. Thus, TUPA could provide a single assay to help diagnose, prognose, and manage many kidney diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据